Analyst Matthew Taylor of Jefferies maintained a Hold rating on Edwards Lifesciences (EW – Research Report), retaining the price target of $71.00.
Matthew Taylor has given his Hold rating due to a combination of factors surrounding Edwards Lifesciences’ current market position and future growth prospects. The company has not experienced significant market share shifts following recent data from the SMART trial, and management does not anticipate any changes in the near future. This stability in market share is supported by high-frequency data indicating that the company’s Transcatheter Aortic Valve Replacement (TAVR) performance in the US aligns with or exceeds expectations.
Despite some loss of TAVR market share in Japan due to competitive pricing, Edwards Lifesciences remains optimistic about long-term growth through potential guideline updates and expansion into less penetrated markets outside the US. Additionally, while there are ongoing capacity constraints, the company is making progress in resource allocation and training for its Evoque product. However, the cautious approach to mergers and acquisitions and the potential risks from tariff exposure in Europe contribute to the Hold rating, as these factors present both opportunities and challenges for the company’s growth trajectory.
In another report released yesterday, Piper Sandler also maintained a Hold rating on the stock with a $73.00 price target.
Based on the recent corporate insider activity of 127 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com